Trial registration
INFLAMMATION, ULCERATIVE COLITIS
ISRCTN16847938Although selnoflast was well‐tolerated and reached sufficient plasma and tissue exposure to inhibit the NLRP3 inflammasome, there were no meaningful changes in sigmoid colon histology or markers of inflammation. No major therapeutic effect is expected in ulcerative colitis.

Chui Fung Chong and Andreas Christ contributed equally to this work.